Reuters logo
BRIEF-Lundbeck, Otsuka get positive opinion for schizophrenia drug
September 20, 2013 / 11:23 AM / 4 years ago

BRIEF-Lundbeck, Otsuka get positive opinion for schizophrenia drug

COPENHAGEN, Sept 20 (Reuters) - Danish pharmaceutical group H. Lundbeck A/S said on Friday: * It and Japanese partner Otsuka Pharmaceutical Co., Ltd. ,4768.T> have receive positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) * Committee recommends marketing authorisation for Abilify Maintena (aripiprazole), a treatment for the maintenance of schizophrenia

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below